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1. Introduction 
In addition to neurotoxin, certain Elapidae venoms, 
i.e. those from the genera Na/a and Haemachatus, 
contain cardiotoxin homologues (cytotoxins) as 
their major protein constituents [ 1]. Recently, a
number of publications have appeared on the amino 
acid sequences of snake venom cardiotoxins [2-15]. 
During the course of our study on the purification 
and characterization f toxic components of the 
venom ofNa/a na/a atra, we separated four cardio- 
toxic proteins. In our previous report [5], we de- 
scribed the sequence of cardiotoxin analogue I, one 
of the above four cardiotoxins. It has been shown 
that these proteins are highly homologous to the 
neurotoxins although their toxicity is at least an 
order of magnitude l ss. This naturally poses the 
question as to how such a difference in toxicity can 
arise in toxins with a high degree of homology. We 
considered that the determination f the primary 
structure of these cardiotoxins might reveal the 
significance of these observations a well as aid the 
identification of the functionally important amino 
acid positions. 
This paper deals with the amino acid sequence of 
cardiotoxin which was obtained at a yield of about 
16.4% from the crude venom ofNa/a na/a atra and 
was the most abundant protein in the venom. In 1970 
Narita and Lee [2] reported the complete amino acid 
sequence of cardiotoxin. However, our results revealed 
the presence of Leu-Val at position 48-49 and not 
Val-Leu as reported by Narita and Lee. 
* To whom inquiries about his article should be directed. 
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2. Materials and methods 
Lyophilized Na]a na]a atra venom was obtained 
from Sigma Chemical Co., USA. The venom dissolved 
in 1% acetic acid was applied on a column of Sepha- 
dex G-50 equilibrated with the same medium. The 
protein fraction with a molecular weight of about 
6000-7500 Was freeze-dried and applied to a CM- 
cellulose column, equilibrated with a 0.005 M sodium 
acetate buffer, pH 5.8. Fractions were eluted with 
sodium acetate buffer which was applied to,the 
column in the form of a linear gradient of concentra- 
tion and pH (from 0.005 M, pH 5.8, to 0.5 M, pH 
6.5). Each fraction was gel-filtered to remove sodium 
acetate, and the homogeneity was confirmed by disc 
gel electrophoresis. The third fraction which was 
cytotoxic to Yoshida sarcoma cells had an amino 
acid composition consistent with that of cardiotoxin. 
This fraction contained the major protein isolated 
from the crude venom and represented a yield of 
16.4% of the original material. Its LD5o in mice (NIH 
strain) following intraperitoneal injection was deter- 
mined according to the method of Litchfield and 
Wilcoxon [ 16]. Chick biventer cervicis muscle prepara- 
tion [17] was used for testing the action on skeletal 
muscle. 
The reduced and S-carboxymethylated (RCM) 
cardiotoxin was prepared by the method reported by 
Crestfield [18]. Amino acid analyses of cardiotoxin 
and the peptides generated by cyanogen bromide 
cleavage or tryptic digestion of the RCM-toxin were 
performed with the standard method using an Hitachi 
KLA 3B amino acid analyzer. Sequence analyses were 
conducted by the modified Edman procedure [19,20], 
and the phenylthiohydantoin amino acids were identi- 
fied by thin layer chromatography employing several 
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solvent systems [21-23].  Carboxypeptidase A diges- 
tion was performed according to standard methods 
[24]. Cyanogen bromide cleavage of the RCM-toxin 
was carried out in 70% formic acid by the method of 
Gross and Witkop [25]. The resulting peptides were 
fractionated on a column of Sephadex G-25 using 0.2 
M acetic acid as an eluate and were further purified 
on a column of DEAE-cellulose. Tryptic peptides were 
separated by high voltage paper electrophoresis at ,  
pH 3.6, and paper chromatography in a solvent system 
of 1-butanol-acetic a id-water (4:1:5, by vol), 
water-saturated phenol, or 1-butanol-acetic a id- 
pyridine-water (15:3:10:12). 
3. Results and discussion 
By the CM-cellulose chromatography of the 
fraction No. IV obtained by gel filtration of the 
venom ofNa]a na]a atra using Sephadex G-50, at 
least four kinds of cardiotoxinqike components were 
fractionated in an homogeneous state by disc gel 
electrophoresis. Cardiotoxin was the most abundant 
protein which was isolated from the venom of Na]a 
naja atr~ The LDso of cardiotoxin in mice after 
intraperitoneal injection was estimated to be 68 (65 
to 70)/ag/g body weight. The mol. wt. was estimated 
by gel filtration to be about 7000. Based on this value 
and on the amino acid analysis, one molecule of 
cardiotoxin contains about 60 amino acid residues: 
Asp 5.69, Thr 2.76, Ser 1.96, Pro 5.30, Gly 1.75, Ala 
1.79, Cys 6.51, Val 5.94, Met 1.70, lie 1.0, Leu 5.48, 
Tyr 2.55, Phe 1.93, Lys 7.40, Arg 2.04. 
Thirty two stepwise Edman degradation of RCM- 
cardiotoxin revealed the amino-terminal sequence to 
be: H -Leu-Lys -Cys -Asn-Lys -Leu-Va l -P ro -  Leu- 
Phe-Tyr -Lys -Thr -Cys -Pro -A la -G ly -Lys -Asn-  
Leu-Cys -Tyr -Lys -Met -Phe-Met -Va l -A la -Thr -  
Pro-Lys-Val  . . . .  
The carboxy-terminal fragment CB-III, obtained 
by the cyanogen bromide cleavage of the RCM-toxin, 
in which homoserine was absent, contained 34 amino 
Table 1 
Amino acid composition of cardiotoxin and peptides generated by CNBr cleavage 
CNBr fragments 
Amino acid Cartiotoxin CB-I CB-II CB-III 
CM-Cysteine - 1.7(3) 3.1(5) 
Aspartic acid 6.6(6) 2.5(2) 4.1(4) 
Threonine 2.9(3) 1.1(1) 1.7(2) 
Serine 2.7(2) 0.6(0) 1.6(2) 
Glutamic acid 0 0 0 
Proline 5.8(5) 2.1 (2) 2.1 (3) 
Glycine 2.3(2) 1.0___~(1) 1.0___(1) 
Alanine 1.8(2) 0.9(1) 0.9(1) 
Valine 4.6(7) 1.4(1) 3.8(6) 
Methionine 2.0(2) 0 0 
lsoleucine 0.9(1) 0 0.7 (1) 
Leucine 5.7 (6) 3.1 (4) 2.1 (2) 
Tyrosine 2.7(3) 1.5(2) 1.0(1) 
Phenylalanine 2.1(2) 1.2(1) 1.0(1) 0.5(0) 
Tryptophan 0 0 0 
Half-Cystine 7.7(8) 0 0 
Lysine 7.9(9) 4.0(5) 3.4(4) 
Histidine 0 0 0 
Homoserine - 0.9(1) 0.9(1) 0 
Arginine 2.0___(2) 0.5(0) 1.6(2) 
Numbers in parentheses r present the values to the nearest integer. In cardiotoxin, the 
value of arginine was taken as 2.0, in CBq and CB-III, the value of glycine was taken 
as 1.0, and in fragment CB-II, the value of phenylalanine was taken as 1.0. 
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Table 2 
Amino acid composition of tryptic peptides of CB-I of cardiotoxin 
July 1976 
Amino Acid T-1 T-2 T-2' T-3 T-4 T-5 T-6 CB-I 
CM-Cystein 1.0(1) 1.0(1) 1.0(1) 3 
Aspartic acid 1.1(1) 1.1(1) 2 
Threonine 0.9(1) 1 
Serine 0 
Glutamic acid 0 
Proline 1.0__(1) 1.1(1) 2 
Glycine 1.0(1) 1 
Alanine 1.0(1) 1 
Valine 0.9( 1 ) 1 
Methionine 0 
Isoleucine 0 
Leucine 1.0(1) 2.0(2) 1.1(1) 4 
Tyrosine 0.8(1) 1.1(1) 2 
Phenylalanine 0.9(1) 1 
Tryptophan 0 
Half-Cystine 0 
Lysine 1.0____(1) 1.0.___(1) 1.0___(1) 1.0__._(1) 1.0__._(1) 5 
Histidine 0 
Homoserine 1.0(1) 1 
Arginine 0 
In each column the values of the amino acids underlined were taken as 1.0. The numbers in parentheses 
represent the values to the nearest integer. 
Table 3 
Amino acid composition of tryptic peptides of CB-III of cardiotoxin 
Amino acid T'-I T'-I' T'-2 T'-3 T~4 T'-5 T'6 CB-III 
CM-Cysteine 2.0(2) 2.5(2)  1.0(1) 5 
Aspartic acid 1.3(I) 2.6(2) 1.2(1) 4 
Threonine 1.2(I) I. 0(I ) 2 
Serine 2.0(2) 2 
Glutamic acid 0 
Proline 1.0(1) 1.3(1) 1.1(1) 3 
Glycine 1.2(1) 1 
Alanine ~ 1.2(1) 1 
Valine 1.8(2) 1.6(1) 1.0(1) 1.0(1) 1.3(1) 6 
Methionine 0 
Isoleucine 1.0(1) 1 
Leucine 2.4(2) 2 
Tyrosine 0.8(1) 1 
Phenylalanine 0 
Tryptophan 0 
Lysine 1._0(1) 1.0__._(1) 1.0.___(1) 1.0(1) 4 
Homoserine 0 
Arginine 1.0(1) 1.0__(1) 2 
In each column the values of the amino acid underlined were taken as 1.0. The numbers in parentheses 
represent the values to the nearest integer. 
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1 10 
H-Leu-Lys.Cys.Asn.Lys.Leu-Val.Pro-Leu.Phe.Ty r.Lys.Thr.Cys.Pro. 
• ~--T-1----~ .~----T-5----~ .<---T-2' ~ ~. T-2----~ 4. 
• CB-1 
20 30 
Ala.Gly.Lys.Asn.Leu'Cys-Tyr'Lys'Met'Phe'Met'Val'Ala'Thr'Pro" 
--T-4-------* .* T-3 ~ ~T-6~ ~ T ' -2 - -  
• ÷CB-II-~ • 
40 
Lys.Val.Pro.Val.Lys.Arg.Gly.Cys.Ile.Asp-Val-Cys.Pro-Lys.Ser. 
---~- ~---T'-I • ~T ' - I~  .* T'-4 • 
CB-III 
50 60 
Ser. Leu-Leu.Val. Lys-Tyr.Val.Cys-Cy s. Asn.Th r. Asp. Arg.Cys.Asn-OH 
- - -T ' -3  • < T'-5 -~ -~-T'-6---~ 
Fig. 1. Amino acid sequence of cardiotoxin from Formosan cobra 
venom (Na/a na/a atra). Horizontal arrows above and below amino 
acid residues denote the sequence of CNBr fragments derived from 
RCM-toxin and tryptic peptides. Right- and left-handed arrows how 
that the sequence was elucidated, respectively, byEdman degrada- 
tion or by the action of carboxypeptidase A. T and T' represent the 
peptides produced by tryptic digestion of fragments CB-I and CB-III, 
respectively. 
acid residues. Stepwise Edman degradation gave all of 
the amino acid residues, v.s. -Va l -A la -Thr -P ro -  
Lys -Va l -P ro -Va l -Lys -Arg -G ly -Cys - I le -Asp-  
Va l -Cys -Pro -Lys -Ser -Ser -Leu-Leu-Va l -Lys -  
Tyr -Va l -Cys -Cys ,Asn-Thr -Asp-Arg -Cys -Asn-  
OH. 
The carboxy-terminal sequence was then examined 
by the use of carboxypeptidase A. After 24 h incuba- 
tion, aspargine and carboxymethylcysteine were 
liberated on the ratio of Asn:Cys(CM)=1.0:0.5. From 
this result, the carboxy-terminal sequence was 
considered to be -Cys -Asn-Asn-OH.  To ascertain 
the carboxy-terminal sequence, the RCM-toxin was 
digested with trypsin and the product was found to 
be a peptide consisting of Asp:Cys(Cm)=l.0:0.8. 
From these results, the cartoxy-terminal sequence 
was determined to be -Cys-Asn-OH.  
The sequence was further ascertained by separation 
of the tryptic peptides from the fragments derived 
from the cyanogen bromide cleavage of cardiotoxin. 
The RCM-toxin was cleaved by cyanogen bromide 
in 70% formic acid for 24 h at 37°C and the resulting 
peptide fragments were fractionated by gel filtration 
on a column of Sephadex G-25. High mol. wt. frag- 
ments CB-I and CB-III were further purified by 
chromatography on a column of DEAE-cellulose. The 
low mol. wt. fragment CB-II, which appeared in the 
column volume of gel filtration procedure, was 
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further purified by paper electrophoresis and paper 
chromatography. 
The amino acid compositions of these peptides 
are given in table 1. The fragments CB-I and CB-III, 
generated from the cyanogen bromide cleavage of 
the RCM-toxin were digested by trypsin and the 
resulting peptides were separated by high voltage 
paper electrophoresis and paper chromatography. The 
amino acid compositions of the peptides were deter- 
mined by amino acid analyses and are shown in 
tables 2 and 3. The central fragment CB-II, which 
contained homoserine and was located between the 
amino- and carboxy-terminal fragments, was deter- 
mined by phenylalanyl homoserine. On the basis 
of the above results, the amino acid sequence of 
cardiotoxin was found to be CB-I-II-III. 
The primary sequence of cardiotoxin can now be 
expressed as shown in fig.1. The amino acid sequence 
differs from that of cardiotoxin reported by Narita 
48 49 48 49 
and Lee in having Leu-Val in place of Val-Leu. How- 
ever, a reinvestigation of the sequence of their tryptic 
peptide corresponding to the present T'-3 by Narita 
[26] has led to a revision to the sequence which now 
is in agreement with that determined in this investiga- 
tion. 
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